Hutchinson Gilford Progeria Syndrome (HGPS) Therapeutics Market
Market Insights on Hutchinson Gilford Progeria Syndrome (HGPS) Therapeutics covering sales outlook, demand forecast & up-to-date key trends
Hutchinson Gilford Progeria Syndrome (HGPS) Therapeutics Market by Treatment, End User & Region | Forecast 2023 to 2033
Hutchinson-Gilford Progeria Syndrome Market Snapshot
The global Hutchinson Gilford progeria syndrome market is expected to garner a market value of US$ 103.07 Billion in 2023 and is expected to accumulate a market value of US$ 233.05 Billion by registering a CAGR of 8.5% in the forecast period 2023 to 2033. The growth of the Hutchinson-Gilford progeria syndrome market can be attributed to the increasing population of the globe which in turn is contributing to more cases of the illness. The market for Hutchinson Gilford progeria syndrome registered a CAGR of 5.5% in the historical period 2017 to 2022
Hutchinson-Gilford progeria syndrome is a genetic condition characterized by the dramatic, rapid, appearance of aging from childhood. Hutchinson-Gilford progeria syndrome is caused by a mutation in the lamin A (LMNA) gene. With continuous research and development efforts, the medication and treatment are expected to shape the market for the Hutchinson-Gilford progeria syndrome market in the upcoming years.
The affected children develop a characteristic facial experience including prominent eyes, a small chin, protruding ears, thin lips, and a thin nose with a beaked tip. This syndrome also causes hair loss (alopecia), joint abnormalities, aged-looking skin, and a loss of fat under the skin (subcutaneous fat). Moreover, patients of Hutchinson-Gilford progeria syndrome experience severe hardening of the arteries (arteriosclerosis) from childhood. The condition worsens with age and increases the risk of heart attack or stroke even at a young age.
|
Report Attribute |
Details |
|
Expected Market Value (2023) |
US$ 103.07 Billion |
|
Anticipated Forecast Value (2033) |
US$ 233.05 Billion |
|
Projected Growth Rate (2023 to 2033) |
8.5% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
2017 to 2022 Hutchinson Gilford progeria syndrome Market Demand Analysis vs. Forecast 2023 to 2033
According to market research and competitive intelligence provider Future Market Insights- the market for Hutchinson Gilford progeria syndrome reflected a value of 5.5% during the historical period, 2017 to 2022.
Hutchinson-Gilford progeria is a rare condition that affects about one in four Billion new-borns worldwide according to the National Institutes of Health (NIH). Until now more than 130 cases have been reported as per the NIH statistics. The affected patients live up to 30 years maximum, with an average life span of 13 years. Nearly 90% of the patients die from complications related to atherosclerosis. Till 2012 there wasn’t any effective treatment therapy discovered for Hutchinson-Gilford progeria syndrome. The treatments available focused mostly on reducing cardiovascular symptoms and growth abnormalities.
With more efforts for investing in developing medication for treating the ailment, innovative treatment is expected to launch in the upcoming years. Thus, the market for Hutchinson Gilford progeria syndrome is expected to register a CAGR of 8.5% in the forecast period 2023 to 2033.
Which are Some Prominent Drivers of Hutchinson-Gilford Progeria Syndrome Market?
Genetic changes leading to extensive study of Hutchinson-Gilford progeria syndrome
In 2012, findings of the first clinical trial of the drug Lonafarnib, a farnesyltransferase inhibitor (FTI), gave new hope for the treatment of children with Hutchinson-Gilford progeria syndrome. Clinical trial results demonstrated improvement in weight gain, increase in bone mineral density, reduced vascular stiffness, and improved sensorineural hearing in patients with progeria. Previous treatments with growth hormone and Sulforaphane helped in reducing the symptoms and prolonging a child’s life. However, it is essential that the patient regularly visits the cardiologist. Rapamycin is one other drug used before, that was demonstrated to reverse nuclear blebbing, retard cellular senescence, and facilitate the degradation of progerin.
Recently in 2015, the scientists at the Agency for Science, Technology & Research (A*STAR) successfully established a model of Hutchinson-Gilford progeria syndrome. The study conducted by this organization proposed a model which implies that progerin is linked to telomeres. Progerin induces a reduction in heterochromatin, a tightly packed form of DNA, making telomeres in the cell more fragile and susceptible to damage. The damaged telomeres in turn trigger premature cellular aging. This model is radically different from the one believed earlier – the gene progerin caused the nucleus to be deformed, thereby weakening the ability of cells to divide and proliferate. The altered progerin protein makes the nuclear envelope unstable and progressively damages the nucleus, making cells more likely to die prematurely.
Researchers are working to determine how genetic changes are further leading to the characteristic features of Hutchinson-Gilford progeria syndrome. Continuous advancement in research with an increased understanding of human aging will provide valuable insights and aid in the treatment of this disease.
Extensive research activities resulting in the innovation of medication for treating Hutchinson-Gilford progeria syndrome
Research and development activities by major institutes to find novel therapies for age-related conditions are expected to offer lucrative opportunities for market players. For instance, in August 2019, researchers from the Houston Methodist Research Institute at the Texas Medical Center focused on using RNA therapeutics - treatment that is focused on ribonucleic acids, a substance found in all living cells - to slow, and possibly reverse Hutchinson-Gilford Progeria.
Similarly, in July 2019, researchers from the University of Oviedo in Spain found that fecal microbiota transplants can help prematurely old mice live longer. The research may help to design targeted probiotic treatments for age-related conditions such as Hutchinson-Gilford Progeria in humans.
Moreover, in March 2019, researchers at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) and the Universidad de Oviedo identified a new molecular mechanism involved in the premature development of atherosclerosis in mice with Hutchinson-Gilford progeria syndrome. The newly identified therapeutic target can be used for blocking early atherosclerosis in progeria.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhat are the Challenges Faced by the Hutchinson-Gilford Progeria Syndrome Market?
Unavailability of proper medication affecting the growth of Hutchinson-Gilford progeria syndrome
The unavailability of accurate medication and treatment for Hutchinson-Gilford progeria syndrome is the major factor hindering the growth of the market. Despite investing money into research and development, favorable results have not been gained through the same. This has led to a delayed and prolonged process for finding the correct treatment to cure Hutchinson-Gilford's progeria syndrome.
Furthermore, Hutchinson-Gilford progeria syndrome starts showing signs and its presence after two years. This has led to an overall delayed process of taking treatments by patients. Furthermore, the lack of knowledge by healthcare professionals and people is creating obstacles to the growth of the Hutchinson-Gilford progeria syndrome market.
Region-Wise Insights
Progeria Research Foundation Creating Opportunities for Treatment of Hutchinson-Gilford Progeria Syndrome in North America?
Find the Children initiative supporting treatment for Hutchinson-Gilford Progeria Syndrome
In terms of market share and revenue, North America is expected to dominate the Progeria treatment market during the forecast period. This is owing to the improved healthcare infrastructure and the strong presence of key players in the region.
For instance, The USA-based Progeria Research Foundation is the only organization in the world dedicated to finding treatments and a cure for children with Progeria. They launched the 'Find the Children' initiative to search the world for undiagnosed children with Progeria so that they, too, can receive the specialized care they require. Thus, North America is expected to possess a 45% market share of the Hutchinson-Gilford progeria syndrome market in 2023.
Increasing Healthcare Expenditure in Asia Pacific Creating Therapeutics Treatment for Hutchinson-Gilford progeria syndrome Market?
Research and development activities for innovating treatments for Hutchinson-Gilford progeria syndrome
The Asia Pacific region is expected to be the fastest-growing market during the forecast period. Significant growth in the Asia Pacific market is attributed to an increase in healthcare expenditure, an increase in government efforts to support medical tourism, and rapid advances in the biotechnology industry.
Increased healthcare spending by a large segment of the population in emerging markets such as India and China is expected to fuel the region's progeria market during the forecast period. Thus, Asia Pacific is expected to hold a 40% market share of the Hutchinson-Gilford progeria syndrome market in 2023.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Category-Wise Insights
Availability of Various Treatments Making Hospitals and Surgical Centres Convenient for Treatment for Hutchinson Gilford Progeria Syndrome Market?
Favorable reimbursement policies make hospitals a viable option for treatment
On the basis of end-user, the Hutchinson Gilford progeria syndrome market is segmented into Hospitals & Surgical Centres, Specialty Clinics, Others
The hospitals & surgical centers segment is expected to hold the largest market share for Hutchinson Gilford progeria syndrome. This is owing to the availability of various diagnostics, testing equipment, and healthcare expertise in hospitals. In addition, the presence of healthcare experts and cardiologists is playing a key role in the wide usage of hospitals for the treatment of Hutchinson-Gilford progeria syndrome.
In addition, initiatives by government authorities to support the treatment of Hutchinson Gilford progeria syndrome, especially in hospitals are favoring the growth of the same. Moreover, reimbursement schemes and their benefits are making hospitals a go-to option for the treatment of Hutchinson Gilford progeria syndrome. Thus, hospitals & surgical centers are expected to hold 50% market share for the Hutchinson Gilford progeria syndrome market in 2023.
Market Competition
Key players in the Hutchinson-Gilford progeria syndrome market are Eiger BioPharmaceuticals, Teva Pharmaceutical, Inc., Amgen, Sanofi, Novartis AG, Schering-Plough, PRG Science & Technology Co., Ltd, Micro Interventional Devices Inc, Boston Scientific Corporation, CryoLife Inc.
- In November 2020, The USA Food and Drug Administration (FDA) approved the first-ever drug Zokinvy (lonafarnib) for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and processing-deficient Progeroid Laminopathies, according to Eiger BioPharmaceuticals, Inc., which focuses on the development and commercialization of targeted therapies for severe rare and ultra-rare diseases. An oral medication called Zokinvy, which is a farnesyltransferase inhibitor, aids in preventing the accumulation of defective progerin or progerin-like protein.
- In May 2022, for the treatment of Hutchinson-Gilford progeria syndrome (HGPS or progeria) and processing-deficient progeroid laminopathies (PL) in Japan, Eiger Biopharmaceuticals Inc., and AnGes Inc. announced that the two companies had entered into an agreement for the regulatory approval, marketing, and distribution of Zokinvy (lonafarnib).
Report Scope
|
Report Attribute |
Details |
|
Market Value in 2023 |
US$ 103.07 Billion |
|
Market Value in 2033 |
US$ 233.05 Billion |
|
Growth Rate |
CAGR of 8.5% from 2023 to 2033 |
|
Base Year for Estimation |
2022 |
|
Historical Data |
2017 to 2022 |
|
Forecast Period |
2023 to 2033 |
|
Quantitative Units |
Revenue in USD Billion and CAGR from 2023 to 2033 |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Customization |
Available Upon Request |
Key Segments Profiled in the Hutchinson-Gilford Progeria Syndrome Market Survey
Treatment:
- Farnesyltransferase Inhibitor (FTI)
- MRI scan
- Hearing tests
- Cardiovascular
- Others
End User:
- Hospitals & Surgical Centres
- Specialty Clinics
- Others
Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa(MEA)
Frequently Asked Questions
At what rate did the Hutchinson Gilford progeria syndrome market flourish from 2017 to 2022?
From 2017 to 2022, the Hutchinson-Gilford progeria syndrome market grew at a CAGR of 5.5%
What will be the growth rate of the global Hutchinson Gilford progeria syndrome market during the forecast period?
The global Hutchinson-Gilford progeria syndrome market is expected to grow with an 8.5% CAGR from 2023 to 2033.
What will be the projected market size of the Hutchinson Gilford progeria syndrome market by 2033?
As of 2033, the Hutchinson-Gilford progeria syndrome market is expected to reach US$ 233.05 Billion
Which end user segment is expected to dominate the global Hutchinson Gilford progeria syndrome market during 2033?
The hospitals and surgical centers segment are expected to hold 50% of the market share in 2023 for Hutchinson Gilford progeria syndrome market.
How is the North America Hutchinson Gilford progeria syndrome market projected to grow in 2033?
North America is expected to possess a 45% market share for Hutchinson Gilford progeria syndrome market in 2023.
How is the Asia Pacific Hutchinson Gilford progeria syndrome market projected to grow in 2033?
Asia Pacific Hutchinson Gilford progeria syndrome market size is expected to possess a 40% market share in 2023.
Table of Content
1. Executive Summary | Hutchinson Gilford Progeria Syndrome (HGPS) Therapeutics Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033 5.3.1. Farnesyltransferase Inhibitor (FTI) 5.3.2. MRI scan 5.3.3. Hearing tests 5.3.4. Cardiovascular 5.3.5. Others 5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-user 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By End-user, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-user, 2023 to 2033 6.3.1. Hospitals & Surgical Centres 6.3.2. Specialty Clinics 6.3.3. Others 6.4. Y-o-Y Growth Trend Analysis By End-user, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By End-user, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. Introduction 7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 7.3.1. North America 7.3.2. Latin America 7.3.3. Europe 7.3.4. South Asia 7.3.5. East Asia 7.3.6. Oceania 7.3.7. Middle East and Africa(MEA) 7.4. Market Attractiveness Analysis By Region 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 8.2.1. By Country 8.2.1.1. USA 8.2.1.2. Canada 8.2.2. By Treatment 8.2.3. By End-user 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Treatment 8.3.3. By End-user 8.4. Key Takeaways 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. Brazil 9.2.1.2. Mexico 9.2.1.3. Rest of Latin America 9.2.2. By Treatment 9.2.3. By End-user 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Treatment 9.3.3. By End-user 9.4. Key Takeaways 10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Germany 10.2.1.2. United Kingdom 10.2.1.3. France 10.2.1.4. Spain 10.2.1.5. Italy 10.2.1.6. Rest of Europe 10.2.2. By Treatment 10.2.3. By End-user 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Treatment 10.3.3. By End-user 10.4. Key Takeaways 11. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. India 11.2.1.2. Malaysia 11.2.1.3. Singapore 11.2.1.4. Thailand 11.2.1.5. Rest of South Asia 11.2.2. By Treatment 11.2.3. By End-user 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Treatment 11.3.3. By End-user 11.4. Key Takeaways 12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. China 12.2.1.2. Japan 12.2.1.3. South Korea 12.2.2. By Treatment 12.2.3. By End-user 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Treatment 12.3.3. By End-user 12.4. Key Takeaways 13. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. Australia 13.2.1.2. New Zealand 13.2.2. By Treatment 13.2.3. By End-user 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Treatment 13.3.3. By End-user 13.4. Key Takeaways 14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. GCC Countries 14.2.1.2. South Africa 14.2.1.3. Israel 14.2.1.4. Rest of Middle East and Africa(MEA) 14.2.2. By Treatment 14.2.3. By End-user 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Treatment 14.3.3. By End-user 14.4. Key Takeaways 15. Key Countries Market Analysis 15.1. USA 15.1.1. Pricing Analysis 15.1.2. Market Share Analysis, 2022 15.1.2.1. By Treatment 15.1.2.2. By End-user 15.2. Canada 15.2.1. Pricing Analysis 15.2.2. Market Share Analysis, 2022 15.2.2.1. By Treatment 15.2.2.2. By End-user 15.3. Brazil 15.3.1. Pricing Analysis 15.3.2. Market Share Analysis, 2022 15.3.2.1. By Treatment 15.3.2.2. By End-user 15.4. Mexico 15.4.1. Pricing Analysis 15.4.2. Market Share Analysis, 2022 15.4.2.1. By Treatment 15.4.2.2. By End-user 15.5. Germany 15.5.1. Pricing Analysis 15.5.2. Market Share Analysis, 2022 15.5.2.1. By Treatment 15.5.2.2. By End-user 15.6. United Kingdom 15.6.1. Pricing Analysis 15.6.2. Market Share Analysis, 2022 15.6.2.1. By Treatment 15.6.2.2. By End-user 15.7. France 15.7.1. Pricing Analysis 15.7.2. Market Share Analysis, 2022 15.7.2.1. By Treatment 15.7.2.2. By End-user 15.8. Spain 15.8.1. Pricing Analysis 15.8.2. Market Share Analysis, 2022 15.8.2.1. By Treatment 15.8.2.2. By End-user 15.9. Italy 15.9.1. Pricing Analysis 15.9.2. Market Share Analysis, 2022 15.9.2.1. By Treatment 15.9.2.2. By End-user 15.10. India 15.10.1. Pricing Analysis 15.10.2. Market Share Analysis, 2022 15.10.2.1. By Treatment 15.10.2.2. By End-user 15.11. Malaysia 15.11.1. Pricing Analysis 15.11.2. Market Share Analysis, 2022 15.11.2.1. By Treatment 15.11.2.2. By End-user 15.12. Singapore 15.12.1. Pricing Analysis 15.12.2. Market Share Analysis, 2022 15.12.2.1. By Treatment 15.12.2.2. By End-user 15.13. Thailand 15.13.1. Pricing Analysis 15.13.2. Market Share Analysis, 2022 15.13.2.1. By Treatment 15.13.2.2. By End-user 15.14. China 15.14.1. Pricing Analysis 15.14.2. Market Share Analysis, 2022 15.14.2.1. By Treatment 15.14.2.2. By End-user 15.15. Japan 15.15.1. Pricing Analysis 15.15.2. Market Share Analysis, 2022 15.15.2.1. By Treatment 15.15.2.2. By End-user 15.16. South Korea 15.16.1. Pricing Analysis 15.16.2. Market Share Analysis, 2022 15.16.2.1. By Treatment 15.16.2.2. By End-user 15.17. Australia 15.17.1. Pricing Analysis 15.17.2. Market Share Analysis, 2022 15.17.2.1. By Treatment 15.17.2.2. By End-user 15.18. New Zealand 15.18.1. Pricing Analysis 15.18.2. Market Share Analysis, 2022 15.18.2.1. By Treatment 15.18.2.2. By End-user 15.19. GCC Countries 15.19.1. Pricing Analysis 15.19.2. Market Share Analysis, 2022 15.19.2.1. By Treatment 15.19.2.2. By End-user 15.20. South Africa 15.20.1. Pricing Analysis 15.20.2. Market Share Analysis, 2022 15.20.2.1. By Treatment 15.20.2.2. By End-user 15.21. Israel 15.21.1. Pricing Analysis 15.21.2. Market Share Analysis, 2022 15.21.2.1. By Treatment 15.21.2.2. By End-user 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Treatment 16.3.3. By End-user 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. Eiger BioPharmaceuticals 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.2. Teva Pharmaceutical, Inc. 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.3. Amgen 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.4. Sanofi 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.5. Novartis AG 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.6. Schering-Plough 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.7. PRG Science & Technology Co., Ltd. 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.8. Micro Interventional Devices Inc. 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.9. Boston Scientific Corporation 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 17.1.10. CryoLife Inc. 17.1.10.1. Overview 17.1.10.2. Product Portfolio 17.1.10.3. Profitability by Market Segments 17.1.10.4. Sales Footprint 17.1.10.5. Strategy Overview 17.1.10.5.1. Marketing Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033 Table 2: Global Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 3: Global Market Value (US$ Million) Forecast by End-user, 2018 to 2033 Table 4: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 5: North America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 6: North America Market Value (US$ Million) Forecast by End-user, 2018 to 2033 Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 8: Latin America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 9: Latin America Market Value (US$ Million) Forecast by End-user, 2018 to 2033 Table 10: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 11: Europe Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 12: Europe Market Value (US$ Million) Forecast by End-user, 2018 to 2033 Table 13: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 14: South Asia Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 15: South Asia Market Value (US$ Million) Forecast by End-user, 2018 to 2033 Table 16: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 17: East Asia Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 18: East Asia Market Value (US$ Million) Forecast by End-user, 2018 to 2033 Table 19: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 20: Oceania Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 21: Oceania Market Value (US$ Million) Forecast by End-user, 2018 to 2033 Table 22: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 23: MEA Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 24: MEA Market Value (US$ Million) Forecast by End-user, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 2: Global Market Value (US$ Million) by End-user, 2023 to 2033 Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033 Figure 4: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033 Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033 Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033 Figure 7: Global Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 8: Global Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 9: Global Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 10: Global Market Value (US$ Million) Analysis by End-user, 2018 to 2033 Figure 11: Global Market Value Share (%) and BPS Analysis by End-user, 2023 to 2033 Figure 12: Global Market Y-o-Y Growth (%) Projections by End-user, 2023 to 2033 Figure 13: Global Market Attractiveness by Treatment, 2023 to 2033 Figure 14: Global Market Attractiveness by End-user, 2023 to 2033 Figure 15: Global Market Attractiveness by Region, 2023 to 2033 Figure 16: North America Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 17: North America Market Value (US$ Million) by End-user, 2023 to 2033 Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033 Figure 19: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 22: North America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 23: North America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 24: North America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 25: North America Market Value (US$ Million) Analysis by End-user, 2018 to 2033 Figure 26: North America Market Value Share (%) and BPS Analysis by End-user, 2023 to 2033 Figure 27: North America Market Y-o-Y Growth (%) Projections by End-user, 2023 to 2033 Figure 28: North America Market Attractiveness by Treatment, 2023 to 2033 Figure 29: North America Market Attractiveness by End-user, 2023 to 2033 Figure 30: North America Market Attractiveness by Country, 2023 to 2033 Figure 31: Latin America Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 32: Latin America Market Value (US$ Million) by End-user, 2023 to 2033 Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033 Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 37: Latin America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 38: Latin America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 40: Latin America Market Value (US$ Million) Analysis by End-user, 2018 to 2033 Figure 41: Latin America Market Value Share (%) and BPS Analysis by End-user, 2023 to 2033 Figure 42: Latin America Market Y-o-Y Growth (%) Projections by End-user, 2023 to 2033 Figure 43: Latin America Market Attractiveness by Treatment, 2023 to 2033 Figure 44: Latin America Market Attractiveness by End-user, 2023 to 2033 Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033 Figure 46: Europe Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 47: Europe Market Value (US$ Million) by End-user, 2023 to 2033 Figure 48: Europe Market Value (US$ Million) by Country, 2023 to 2033 Figure 49: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 52: Europe Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 53: Europe Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 54: Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 55: Europe Market Value (US$ Million) Analysis by End-user, 2018 to 2033 Figure 56: Europe Market Value Share (%) and BPS Analysis by End-user, 2023 to 2033 Figure 57: Europe Market Y-o-Y Growth (%) Projections by End-user, 2023 to 2033 Figure 58: Europe Market Attractiveness by Treatment, 2023 to 2033 Figure 59: Europe Market Attractiveness by End-user, 2023 to 2033 Figure 60: Europe Market Attractiveness by Country, 2023 to 2033 Figure 61: South Asia Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 62: South Asia Market Value (US$ Million) by End-user, 2023 to 2033 Figure 63: South Asia Market Value (US$ Million) by Country, 2023 to 2033 Figure 64: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 65: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 66: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 67: South Asia Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 68: South Asia Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 69: South Asia Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 70: South Asia Market Value (US$ Million) Analysis by End-user, 2018 to 2033 Figure 71: South Asia Market Value Share (%) and BPS Analysis by End-user, 2023 to 2033 Figure 72: South Asia Market Y-o-Y Growth (%) Projections by End-user, 2023 to 2033 Figure 73: South Asia Market Attractiveness by Treatment, 2023 to 2033 Figure 74: South Asia Market Attractiveness by End-user, 2023 to 2033 Figure 75: South Asia Market Attractiveness by Country, 2023 to 2033 Figure 76: East Asia Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 77: East Asia Market Value (US$ Million) by End-user, 2023 to 2033 Figure 78: East Asia Market Value (US$ Million) by Country, 2023 to 2033 Figure 79: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 80: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 81: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 82: East Asia Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 83: East Asia Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 84: East Asia Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 85: East Asia Market Value (US$ Million) Analysis by End-user, 2018 to 2033 Figure 86: East Asia Market Value Share (%) and BPS Analysis by End-user, 2023 to 2033 Figure 87: East Asia Market Y-o-Y Growth (%) Projections by End-user, 2023 to 2033 Figure 88: East Asia Market Attractiveness by Treatment, 2023 to 2033 Figure 89: East Asia Market Attractiveness by End-user, 2023 to 2033 Figure 90: East Asia Market Attractiveness by Country, 2023 to 2033 Figure 91: Oceania Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 92: Oceania Market Value (US$ Million) by End-user, 2023 to 2033 Figure 93: Oceania Market Value (US$ Million) by Country, 2023 to 2033 Figure 94: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 95: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 96: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 97: Oceania Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 98: Oceania Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 99: Oceania Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 100: Oceania Market Value (US$ Million) Analysis by End-user, 2018 to 2033 Figure 101: Oceania Market Value Share (%) and BPS Analysis by End-user, 2023 to 2033 Figure 102: Oceania Market Y-o-Y Growth (%) Projections by End-user, 2023 to 2033 Figure 103: Oceania Market Attractiveness by Treatment, 2023 to 2033 Figure 104: Oceania Market Attractiveness by End-user, 2023 to 2033 Figure 105: Oceania Market Attractiveness by Country, 2023 to 2033 Figure 106: MEA Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 107: MEA Market Value (US$ Million) by End-user, 2023 to 2033 Figure 108: MEA Market Value (US$ Million) by Country, 2023 to 2033 Figure 109: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 110: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 111: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 112: MEA Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 113: MEA Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 114: MEA Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 115: MEA Market Value (US$ Million) Analysis by End-user, 2018 to 2033 Figure 116: MEA Market Value Share (%) and BPS Analysis by End-user, 2023 to 2033 Figure 117: MEA Market Y-o-Y Growth (%) Projections by End-user, 2023 to 2033 Figure 118: MEA Market Attractiveness by Treatment, 2023 to 2033 Figure 119: MEA Market Attractiveness by End-user, 2023 to 2033 Figure 120: MEA Market Attractiveness by Country, 2023 to 2033
Recommendations
Explore Healthcare Insights
View Reports
